KalVista Pharmaceuticals, Inc.
KALV
$13.55
-$0.05-0.37%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 81.07M | 91.00M | 93.47M | 86.17M | 84.87M |
| Gross Profit | -81.07M | -91.00M | -93.47M | -86.17M | -84.87M |
| SG&A Expenses | 100.36M | 80.64M | 62.09M | 54.28M | 38.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 181.42M | 171.63M | 155.57M | 140.45M | 123.72M |
| Operating Income | -181.42M | -171.63M | -155.57M | -140.45M | -123.72M |
| Income Before Tax | -171.62M | -156.39M | -141.77M | -126.64M | -108.30M |
| Income Tax Expenses | 4.25M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -175.87 | -156.39 | -141.77 | -126.64 | -108.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.87M | -156.39M | -141.77M | -126.64M | -108.30M |
| EBIT | -181.42M | -171.63M | -155.57M | -140.45M | -123.72M |
| EBITDA | -180.52M | -170.76M | -154.72M | -139.63M | -122.93M |
| EPS Basic | -3.73 | -3.64 | -3.54 | -3.40 | -3.14 |
| Normalized Basic EPS | -2.30 | -2.29 | -2.23 | -2.15 | -1.98 |
| EPS Diluted | -3.73 | -3.64 | -3.54 | -3.40 | -3.14 |
| Normalized Diluted EPS | -2.30 | -2.29 | -2.23 | -2.15 | -1.98 |
| Average Basic Shares Outstanding | 189.16M | 171.24M | 159.11M | 147.29M | 138.05M |
| Average Diluted Shares Outstanding | 189.16M | 171.24M | 159.11M | 147.29M | 138.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |